The conversation is shifting from 'What is the best drug?' to 'What is the best drug for this specific patient's biology and lifestyle?'
Tagrisso (Osimertinib) and Rybrevant (Amivantamab) are both used to treat non-small cell lung cancer (NSCLC) with EGFR mutations, but they work differently. Tagrisso is an oral tyrosine kinase inhibitor (TKI) that targets specific mutations like Exon 19 deletions or L858R. Rybrevant is an intravenous bispecific antibody designed to target both EGFR and MET receptors, often used for patients with Exon 20 insertion mutations or those who have progressed on other therapies.
The administration methods for these two lung cancer therapies differ significantly. Tagrisso is a daily oral tablet, which offers convenience for at-home treatment. In contrast, Rybrevant is administered as an intravenous infusion by a healthcare professional in a clinical setting. The choice between these treatments often depends on the specific genetic profile of the tumor and the patient's previous treatment history with other EGFR-targeted therapies.
Rybrevant is sometimes considered as a treatment option for patients with NSCLC who have developed resistance to prior EGFR tyrosine kinase inhibitors like Tagrisso. Because Rybrevant uses a bispecific antibody approach to target both EGFR and MET pathways, it may bypass certain resistance mechanisms that render standard TKIs ineffective. Medical professionals evaluate the specific mutation profile to determine if switching to Rybrevant is the appropriate next step in a patient's therapy plan.
From Columbia University alumni built in San Francisco
"Instead of endless scrolling, I just hit play on BeFreed. It saves me so much time."
"I never knew where to start with nonfiction—BeFreed’s book lists turned into podcasts gave me a clear path."
"Perfect balance between learning and entertainment. Finished ‘Thinking, Fast and Slow’ on my commute this week."
"Crazy how much I learned while walking the dog. BeFreed = small habits → big gains."
"Reading used to feel like a chore. Now it’s just part of my lifestyle."
"Feels effortless compared to reading. I’ve finished 6 books this month already."
"BeFreed turned my guilty doomscrolling into something that feels productive and inspiring."
"BeFreed turned my commute into learning time. 20-min podcasts are perfect for finishing books I never had time for."
"BeFreed replaced my podcast queue. Imagine Spotify for books — that’s it. 🙌"
"It is great for me to learn something from the book without reading it."
"The themed book list podcasts help me connect ideas across authors—like a guided audio journey."
"Makes me feel smarter every time before going to work"
From Columbia University alumni built in San Francisco
